Neuroprotective Drugs Market Report

Global and Region Neuroprotective Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：220
  • REPORT CODE：GMM1023379
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Neuroprotective Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Neuroprotective Drugsmarket, defines the market attractiveness level of Neuroprotective Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Neuroprotective Drugs industry, describes the types of Neuroprotective Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Neuroprotective Drugs market and the development prospects and opportunities of Neuroprotective Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Neuroprotective Drugs market in Chapter 13.

    By Player:

    • Ceregene (USA)

    • Genervon Biopharmaceuticals (Canada)

    • Neuren Pharmaceuticals (Australia)

    • Bionure Inc (USA)

    • NeuroVive Pharmaceutical (Sweden)

    • BHRPharma (Thailand)

    • Allon therapeutics (Canada)

    By Type:

    • Cholinesterase Inhibitors

    • Anti-inflammatory

    • Others

    By End-User:

    • Alzheimer's disease

    • Parkinson's disease

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Neuroprotective Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Neuroprotective Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Neuroprotective Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Neuroprotective Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Neuroprotective Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Neuroprotective Drugs Consumption (2017-2022)

    • 7.2 United States Neuroprotective Drugs Consumption (2017-2022)

    • 7.3 Europe Neuroprotective Drugs Consumption (2017-2022)

    • 7.4 China Neuroprotective Drugs Consumption (2017-2022)

    • 7.5 Japan Neuroprotective Drugs Consumption (2017-2022)

    • 7.6 India Neuroprotective Drugs Consumption (2017-2022)

    • 7.7 South Korea Neuroprotective Drugs Consumption (2017-2022)

    8 Region and Country-wise Neuroprotective Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Neuroprotective Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Neuroprotective Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Neuroprotective Drugs Consumption Forecast (2022-2028)

    • 8.4 China Neuroprotective Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Neuroprotective Drugs Consumption Forecast (2022-2028)

    • 8.6 India Neuroprotective Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Neuroprotective Drugs Consumption Forecast (2022-2028)

    9 Global Neuroprotective Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Neuroprotective Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Cholinesterase Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Anti-inflammatory Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neuroprotective Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Alzheimer's disease Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Parkinson's disease Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Neuroprotective Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Neuroprotective Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Cholinesterase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Anti-inflammatory Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Neuroprotective Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Alzheimer's disease Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Parkinson's disease Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Neuroprotective Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Neuroprotective Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Neuroprotective Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Neuroprotective Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Neuroprotective Drugs Market Competitive Analysis

    • 14.1 Ceregene (USA)

      • 14.1.1 Ceregene (USA) Company Details

      • 14.1.2 Ceregene (USA) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Ceregene (USA) Neuroprotective Drugs Product and Service

    • 14.2 Genervon Biopharmaceuticals (Canada)

      • 14.2.1 Genervon Biopharmaceuticals (Canada) Company Details

      • 14.2.2 Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Product and Service

    • 14.3 Neuren Pharmaceuticals (Australia)

      • 14.3.1 Neuren Pharmaceuticals (Australia) Company Details

      • 14.3.2 Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Product and Service

    • 14.4 Bionure Inc (USA)

      • 14.4.1 Bionure Inc (USA) Company Details

      • 14.4.2 Bionure Inc (USA) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Bionure Inc (USA) Neuroprotective Drugs Product and Service

    • 14.5 NeuroVive Pharmaceutical (Sweden)

      • 14.5.1 NeuroVive Pharmaceutical (Sweden) Company Details

      • 14.5.2 NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Product and Service

    • 14.6 BHRPharma (Thailand)

      • 14.6.1 BHRPharma (Thailand) Company Details

      • 14.6.2 BHRPharma (Thailand) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 BHRPharma (Thailand) Neuroprotective Drugs Product and Service

    • 14.7 Allon therapeutics (Canada)

      • 14.7.1 Allon therapeutics (Canada) Company Details

      • 14.7.2 Allon therapeutics (Canada) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Allon therapeutics (Canada) Neuroprotective Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Neuroprotective Drugs

    • Figure Neuroprotective Drugs Picture

    • Table Global Neuroprotective Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuroprotective Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuroprotective Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Neuroprotective Drugs Consumption by Country (2017-2022)

    • Figure United States Neuroprotective Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Neuroprotective Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Neuroprotective Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Neuroprotective Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Neuroprotective Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neuroprotective Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Neuroprotective Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Neuroprotective Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neuroprotective Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Neuroprotective Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neuroprotective Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neuroprotective Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neuroprotective Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cholinesterase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Anti-inflammatory Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Alzheimer's disease Consumption and Growth Rate (2017-2022)

    • Figure Global Parkinson's disease Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Cholinesterase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Anti-inflammatory Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Alzheimer's disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Parkinson's disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Neuroprotective Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Neuroprotective Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Ceregene (USA) (Foundation Year, Company Profile and etc.)

    • Table Ceregene (USA) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ceregene (USA) Neuroprotective Drugs Product and Service

    • Table Genervon Biopharmaceuticals (Canada) (Foundation Year, Company Profile and etc.)

    • Table Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Product and Service

    • Table Neuren Pharmaceuticals (Australia) (Foundation Year, Company Profile and etc.)

    • Table Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Product and Service

    • Table Bionure Inc (USA) (Foundation Year, Company Profile and etc.)

    • Table Bionure Inc (USA) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bionure Inc (USA) Neuroprotective Drugs Product and Service

    • Table NeuroVive Pharmaceutical (Sweden) (Foundation Year, Company Profile and etc.)

    • Table NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Product and Service

    • Table BHRPharma (Thailand) (Foundation Year, Company Profile and etc.)

    • Table BHRPharma (Thailand) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table BHRPharma (Thailand) Neuroprotective Drugs Product and Service

    • Table Allon therapeutics (Canada) (Foundation Year, Company Profile and etc.)

    • Table Allon therapeutics (Canada) Neuroprotective Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allon therapeutics (Canada) Neuroprotective Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US